It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss. Unlike its predecessor Semaglutide (which only targets GLP-1), Tirzepatide showed 5–7% more weight loss in clinical trials. Compared to Retatrutide, a triple agonist,...

Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss. For research purposes only. This product is supplied...

Tirzepatide was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss. For research purposes only. This product is supplied...

Vasoactive Intestinal Peptide (VIP) is a multifunctional peptide studied for immunomodulation, bronchodilation, and vasodilation. Research highlights its potential in regulating T-cell differentiation, modulating inflammation, supporting cardiovascular function, and providing neuroprotective effects in experimental and autoimmune models. For research...